Dana Mitchell, MD
Nephrology · Houston, TXNPI 1659308450
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $234,970 of the $344,422 with a category attached, or 68.2%. 32 manufacturers reported payments, led by Bayer at 31.0% of the total. 2025 is the largest year on record at $87,842, 6.3 times the $13,997 reported in 2019. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 782 payments — averaging $440.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$107K
- Amgen$96K
- AstraZeneca$78K
- Mallinckrodt Hospital Products Inc.$40K
- Mallinckrodt Enterprises LLC$13K
- GSK$6K
- plus $3K from 26 others
Across 27 payments — averaging $4289.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$116K
What the payments were for
- Consulting fees$51,91515%
- Speaking & faculty fees$234,97068%
- Grants$2,1501%
- Travel & lodging$39,90612%
- Food & beverage$15,4454%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 106 | $106,655 |
| Amgen(2 entities) | 215 | $96,156 |
| AstraZeneca(2 entities) | 182 | $78,490 |
| Mallinckrodt Hospital Products Inc. | 80 | $40,152 |
| Mallinckrodt Enterprises LLC | 22 | $13,220 |
| GSK | 22 | $6,440 |
| Akebia Therapeutics Inc | 44 | $705 |
| Otsuka America Pharmaceutical, Inc. | 17 | $355 |
| Vifor Pharma, Inc. | 18 | $319 |
| OPKO Pharmaceuticals, LLC | 20 | $314 |
| Calliditas Therapeutics US Inc. | 5 | $226 |
| Abbott | 4 | $200 |
| Boehringer Ingelheim | 3 | $157 |
| Aurinia Pharma U.S., Inc. | 7 | $127 |
| Travere Therapeutics, Inc. | 6 | $121 |
| Medtronic | 1 | $106 |
| Novartis | 4 | $89 |
| Fresenius USA Marketing, Inc. | 5 | $82 |
| Novo Nordisk | 4 | $69 |
| Cordis US CORP. | 1 | $68 |
| Ardelyx, Inc. | 2 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Cormedix Inc. | 2 | $38 |
| Sanofi | 2 | $37 |
| Asahi Intecc USA, Inc. | 1 | $36 |
| Pharmacosmos Therapeutics Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Merck | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Amicus Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$344,422 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 75 | $45,656 |
| LokelmaSodium Zirconium Cyclosilicate | 52 | $45,547 |
| RayaldeeCalcifediol | 21 | $42,759 |
| OzempicSemaglutide | 34 | $40,582 |
| KerendiaFinerenone | 39 | $36,877 |
| JanuviaSitagliptin Phosphate | 17 | $9,868 |
| ProcritEpoetin Alfa | 20 | $6,907 |
| Demeclocycline Hcl | 11 | $5,447 |
| RetacritEpoetin Alfa-Epbx | 12 | $3,331 |
| Sevelamer Carbonate | 13 | $2,686 |
| Nifedipine ErNifedipine | 57 | $2,531 |
| Febuxostat | 19 | $1,705 |
| Cinacalcet Hcl | 18 | $1,169 |
| Allopurinol | 114 | $894 |
| Calcitriol | 32 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $78,490 | $91,203127 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $314 | $42,75921 claims |
| Novo NordiskOzempic | $69 | $40,58234 claims |
| BayerKerendia | $106,655 | $36,87739 claims |
| MerckJanuvia | $26 | $9,86817 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $41 | $45218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Houston
- Sreedhar MandayamHouston$752K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Namrata GoelHouston$426K
- Ramachandra MalyaHouston$312K
- John ForingerHouston$215K
- Biruh WorkenehHouston$185K
- Horacio AdrogueHouston$122K
- Anand SaranathanHouston$109K
- Kevin EricksonHouston$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.